Patients undergoing long-term continuous ambulatory peritoneal dialysis (CAPD) sometimes experience ultrafiltration failure. Mesothelial basement membrane thickening and the accumulation of submesothelial fibrotic tissue are common features of the diseased peritoneum. Peritonitis can lead to ultrafiltration failure, but the precise mechanism is not clear. The key enzymes in extracellular matrix (ECM) remodeling, namely matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs), are produced by human peritoneal mesothelial cells. Using peritoneal effluent from 13 CAPD patients with peritonitis and 7 noninfected CAPD control individuals, we examined MMP and TIMP activities by gelatin and reverse zymography. Latent and activated types of MMP-2 and -9, and TIMP-1 and -2 were identified in peritoneal effluent (from all CAPD patients). Levels of latent and activated type MMP-9, as well as of TIMP-1 activities were higher at the onset of peritonitis than either during the recovery phase of peritonitis and/ or in control individuals. Activated MMP-9 activity positively correlated with leukocyte numbers and IL-6 levels in peritoneal effluent. Activities of MMP-2 and TIMP-2 in peritoneal effluent did not change between the onset of peritonitis and recovery. We concluded that increased MMP-9 and TIMP-1 levels might be associated with peritoneal ECM remodeling during peritonitis.

Keywords:
Continuous ambulatory peritoneal dialysis, Extracellular matrix, Interleukin-6, Matrix metalloproteinases, Peritoneal effluent, Peritonitis, Tissue inhibitors of metalloproteinases
1.
Dobbie JW: Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992;12:14–27.
2.
Dobbie JW, Anderson JD, Hind C: Long-term effects of peritoneal dialysis on peritoneal morphology. Perit Dial Int 1994;14(suppl 3):16–20.
3.
Harvey W, Amlot PL: Collagen production by human mesothelial cells in vitro. J Pathol 1983;139:337–347.
4.
Perfumo F, Altieri P, Degl’Innocenti ML, Ghiggeri GM, Caridi G, Trivelli A, Gusmano R: Effects of peritoneal effluents on mesothelial cells in culture: Cell proliferation and extracellular matrix regulation. Nephrol Dial Transplant 1996;11:1803–1809.
5.
Dobbie JW: Ultrastructure and pathology of the peritoneum in peritoneal dialysis; in Gokal R, Nolph KD (eds): The Textbook of Peritoneal Dialysis. Dordrecht, Kluwer Academic, 1994, pp 17–44.
6.
Oules R,Challah S, Brunner FP: Case-control study to determine the cause of sclerosing peritoneal disease. Nephrol Dial Transplant 1988;3:66–69.
7.
Slingeneyer A, Canaud B, Mion C: Permanent loss of ultrafiltration capacity of the peritoneum in long-term peritoneal dialysis: An epidemiological study. Nephron 1983;33:133–138.
8.
Gotloib L, Waisbrut V, Shostak A, Kushnier R: Acute and long-term changes observed in imprints of mouse mesothelium exposed to glucose-enriched, lactated, buffered dialysis solutions. Nephron 1995;70:466–477.
9.
Marshall BC, Santana A, Xu QP, Petersen MJ, Campbell EJ, Hoidal JR, Welgus HG: Metalloproteinases and tissue inhibitor of metalloproteinases in mesothelial cells. J Clin Invest 1993;91:1792–1799.
10.
Stylianou E, Jenner LA, Davies M, Coles GA, Williams JD: Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int 1990;37:1563–1570.
11.
Rennard SI, Jaurand MC, Bignon J, Kawanami O, Ferrans VJ, Davidson J, Crystal RG: Role of pleural mesothelial cells in the production of the submesothelial connective tissue matrix of lung. Am Rev Respir Dis 1984;130:267–274.
12.
Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–275.
13.
Fujimoto S, Hamai K, Sato Y, Yamamoto Y, Eto T: Neutral metalloproteinases in human urine from normal subjects and renal disease patients. Nephrology 1996;2:329–337.
14.
Eickelberg O, Sommerfeld CO, Wyser C, Tamm M, Reichenberger F, Bardin PG, Soler M, Roth M, Perruchoud AP: MMP and TIMP expression pattern in pleural effusions of different origins. Am J Respir Crit Care Med 1997;156:1987–1992.
15.
Murphy G, Reynolds JJ, Bretz U, Baggiolini M: Partial purification of collagenase and gelatinase from human polymorphonuclear leukocytes. Analysis of their actions on soluble and insoluble collagens. Biochem J 1982;203:209–221.
16.
Welgus HG, Campbell EJ, Cury JD, Eisen AZ, Senior RM, Wilhelm SM, Goldberg GI: Neutral metalloproteinases produced by human mononuclear phagocytes. J Clin Invest 1990;86:1496–1502.
17.
Ries C, Petrides PE: Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol Chem Hoppe Seyler 1995;376:345–355.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.